Mutation Detection Kits in Genome Editing Market Report 2025

The mutation detection kits in the genome editing market size has grown rapidly in recent years. It will grow from $1.01 billion in 2024 to $1.14 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth during the historical period can be attributed to increasing research on genetic disorders, rising government funding for genomics, expanding academic and clinical research collaborations, greater availability of advanced molecular biology tools, and growing investments from biotechnology companies.

The mutation detection kits in the genome editing market size are expected to see rapid growth in the next few years. It will grow to $1.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during the forecast period can be attributed to increasing adoption of autonomous mobile robots (AMRs), greater focus on supply chain visibility, rising investment in digital twin technologies, growing demand for real-time asset tracking, and expanding use of industrial automation. Key trends expected in the forecast period include advancements in real-time location systems (RTLS), innovations in AI-powered asset tracking, integration of RFID with IoT platforms, progress in ultra-wideband (UWB) technology, and incorporation of digital twin solutions into industrial automation.

The increasing prevalence of genetic disorders is expected to drive the growth of mutation detection kits in the genome editing market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual's DNA, either inherited from parents or resulting from new genetic mutations. The reported rise in genetic disorders is fueled by greater awareness and advances in diagnostic technologies, which allow for earlier and more accurate identification of these conditions. Mutation detection kits for genome editing help address genetic disorders by precisely identifying disease-causing gene mutations, supporting targeted research and the development of effective therapeutic interventions. For example, in May 2024, the National Health Service, a UK-based government department, reported that approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. As a result, the growing prevalence of genetic disorders is boosting the demand for mutation detection kits in the genome editing market.

Key players in the mutation detection kits market are focusing on developing advanced products, such as ultrasensitive multiplexed assays, to improve accuracy, speed, and sensitivity in detecting genetic mutations. Ultrasensitive multiplexed assays are sophisticated diagnostic tests capable of simultaneously detecting and quantifying multiple genetic mutations at very low levels, enabling faster, more accurate, and comprehensive mutation analysis for improved disease diagnosis and monitoring. For instance, in April 2024, Bio-Rad Laboratories Inc., a US-based research company, launched the ddPLEX ESR1 Mutation Detection Kit, an ultrasensitive multiplexed digital PCR assay designed for breast cancer mutation detection. This kit allows simultaneous identification and precise quantification of seven ESR1 mutations with an analytical sensitivity down to 0.01% variant allele fraction, supporting analysis of both plasma and tissue samples. Such innovations reflect the industry’s focus on enhancing diagnostic accuracy and enabling personalized treatment strategies.

In March 2025, ERS Genomics Limited, an Ireland-based biotechnology company, partnered with Jumpcode Genomics Inc. to advance next-generation sequencing capabilities. Through this partnership, Jumpcode Genomics Inc. plans to leverage ERS Genomics Limited’s CRISPR/Cas9 patent portfolio to improve its next-generation sequencing technologies, achieving higher sensitivity, enhanced efficiency, and expanded applications in areas including basic research, infectious disease detection, molecular diagnostics, and oncology. Jumpcode Genomics Inc., based in the US, provides advanced tools for mutation detection and genome editing.

Major players in the mutation detection kits in genome editing market are F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., QIAGEN N.V., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Promega Corporation, Analytik Jena AG, Twist Bioscience Corporation, New England Biolabs Inc., Applied Biological Materials Inc., Synthego Corporation, Cell Signaling Technology Inc., BioVision Inc., Creative Biogene Corporation.

North America was the largest region in the mutation detection kits in genome editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mutation detection kits genome editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mutation detection kits genome editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Mutation detection kits for genome editing are specialized tools designed to identify and analyze genetic modifications introduced during the editing process. They allow for precise detection of insertions, deletions, and substitutions in deoxyribonucleic acid (DNA) sequences, ensuring accurate validation of editing outcomes. These kits provide critical data for optimizing genome editing techniques and enhancing overall experimental efficiency.

The primary product types of mutation detection kits for genome editing include reagents, kits, and software solutions. Reagents are specialized chemicals or mixtures that facilitate and support precise biochemical reactions in genetic testing, directly affecting accuracy and efficiency. These kits employ various technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases or meganuclease-TAL effector nucleases (TALENs/MegaTALs), zinc finger nucleases (ZFNs), and other genome editing methods. They are applied in multiple areas, including research, clinical diagnostics, drug development, and more, and are utilized by a range of end-users, including academic institutions, hospitals and diagnostic centers, and biotechnology companies.

The mutation detection kits in genome editing market research report is one of a series of new reports that provides mutation detection kits in genome editing market statistics, including the mutation detection kits in genome editing global market size, regional shares, competitors with the mutation detection kits in genome editing market share, detailed mutation detection kits in genome editing market segments, market trends, and opportunities, and any further data you may need to thrive in the mutation detection kits in genome editing. This mutation detection kits in genome editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mutation detection kits genome editing market consists of revenues earned by entities by providing services such as the development of specialized assays, manufacturing and distribution of mutation detection kits, CRISPR validation and off-target analysis services, next-generation sequencing (NGS)-based mutation identification, and supplying bioinformatics tools for interpreting genetic modification data. The market value includes the value of related goods sold by the service provider or included within the service offering. The mutation detection kits genome editing market also includes sales of Sanger sequencing-based mutation detection kits, fluorescent reporter-based detection systems, high-resolution melt analysis (HRMA) kits, and droplet digital PCR (ddPCR) mutation detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.